Biological therapy in inflammatory rheumatic diseases

Issues in Central and Eastern European countries

Márta Péntek, G. Poór, Piotr Wiland, Martina Olejárová, Marek Brzosko, Catalin Codreanu, Nóra Brodszky, L. Gulácsi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collection in inflammatory rheumatic diseases in CEE countries.

Original languageEnglish
JournalEuropean Journal of Health Economics
Volume15
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2014

Fingerprint

Biological Therapy
Rheumatic Diseases
Biological Factors
Bulgaria
Romania
Slovakia
Psoriatic Arthritis
Hungary
Czech Republic
Ankylosing Spondylitis
Poland
Therapeutics
Pharmaceutical Preparations
Uncertainty
Rheumatoid Arthritis
Epidemiology
Economics
Central and Eastern European countries
Therapy
Drugs

Keywords

  • Ankylosing spondylitis
  • Biological therapy
  • Central and Eastern Europe
  • Health services accessibility
  • Psoriatic arthritis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Health Policy
  • Economics, Econometrics and Finance (miscellaneous)
  • Medicine(all)

Cite this

Biological therapy in inflammatory rheumatic diseases : Issues in Central and Eastern European countries. / Péntek, Márta; Poór, G.; Wiland, Piotr; Olejárová, Martina; Brzosko, Marek; Codreanu, Catalin; Brodszky, Nóra; Gulácsi, L.

In: European Journal of Health Economics, Vol. 15, No. SUPPL. 1, 2014.

Research output: Contribution to journalArticle

Péntek, Márta ; Poór, G. ; Wiland, Piotr ; Olejárová, Martina ; Brzosko, Marek ; Codreanu, Catalin ; Brodszky, Nóra ; Gulácsi, L. / Biological therapy in inflammatory rheumatic diseases : Issues in Central and Eastern European countries. In: European Journal of Health Economics. 2014 ; Vol. 15, No. SUPPL. 1.
@article{1745fd91b26f4e6f8d9b1bbc2ad96078,
title = "Biological therapy in inflammatory rheumatic diseases: Issues in Central and Eastern European countries",
abstract = "Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collection in inflammatory rheumatic diseases in CEE countries.",
keywords = "Ankylosing spondylitis, Biological therapy, Central and Eastern Europe, Health services accessibility, Psoriatic arthritis, Rheumatoid arthritis",
author = "M{\'a}rta P{\'e}ntek and G. Po{\'o}r and Piotr Wiland and Martina Olej{\'a}rov{\'a} and Marek Brzosko and Catalin Codreanu and N{\'o}ra Brodszky and L. Gul{\'a}csi",
year = "2014",
doi = "10.1007/s10198-014-0592-6",
language = "English",
volume = "15",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Biological therapy in inflammatory rheumatic diseases

T2 - Issues in Central and Eastern European countries

AU - Péntek, Márta

AU - Poór, G.

AU - Wiland, Piotr

AU - Olejárová, Martina

AU - Brzosko, Marek

AU - Codreanu, Catalin

AU - Brodszky, Nóra

AU - Gulácsi, L.

PY - 2014

Y1 - 2014

N2 - Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collection in inflammatory rheumatic diseases in CEE countries.

AB - Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collection in inflammatory rheumatic diseases in CEE countries.

KW - Ankylosing spondylitis

KW - Biological therapy

KW - Central and Eastern Europe

KW - Health services accessibility

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84905687689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905687689&partnerID=8YFLogxK

U2 - 10.1007/s10198-014-0592-6

DO - 10.1007/s10198-014-0592-6

M3 - Article

VL - 15

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - SUPPL. 1

ER -